Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Holdings Lessened by Algert Global LLC

Algert Global LLC reduced its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 61.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,714 shares of the medical equipment provider’s stock after selling 77,626 shares during the quarter. Algert Global LLC owned about 0.07% of Lantheus worth $5,456,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of LNTH. GAMMA Investing LLC raised its position in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares in the last quarter. Signaturefd LLC increased its position in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares in the last quarter. Nkcfo LLC acquired a new stake in Lantheus during the 2nd quarter valued at $47,000. UMB Bank n.a. raised its position in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. acquired a new position in shares of Lantheus in the 3rd quarter valued at about $51,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

NASDAQ LNTH opened at $90.52 on Monday. The stock’s 50 day simple moving average is $103.13 and its 200 day simple moving average is $96.93. The firm has a market cap of $6.29 billion, a PE ratio of 15.06 and a beta of 0.51. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89.

Analyst Ratings Changes

A number of brokerages have commented on LNTH. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday. Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Redburn Atlantic began coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. Finally, JMP Securities lowered their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.